Form 13-F position report

IOVANCE BIOTHERAPEUTICS INC

Reported by Mirador Capital Partners LP

IOVA CUSIP 462260100 Manager CIK 0001633446

Reported 1,095,740 shares, up 15,452 (1.4%) from the prior quarter.

Reported value 261.3%; share count 1.4% vs. the prior quarter.

Added
% of reported 13F value 1.89% This manager · Q3 2026
Shares 1,095,740 Quarter-end amount reported
Reported value $16,238,867 Fair value at quarter end
Consecutive quarters held 5 Through Q3 2026

Reported position value by quarter

Reported position value by quarter

Each bar is a Form 13-F quarter-end snapshot. It does not show trades made within the quarter.

Reported position value by quarter
Date Holding Value
2021-12-31 765000
2022-03-31 718000
2022-06-30 714000
2022-09-30 608000
2022-12-31 0
2025-09-30 1117604
2025-12-31 2824305
2026-03-31 3767058
2026-06-30 4493998
2026-09-30 16238867

Quarterly position history

How this manager's reported quarter-end position changed over time.

10 quarters
Quarterly reported position history for IOVANCE BIOTHERAPEUTICS INC held by Mirador Capital Partners LP.
Quarter Activity Shares Change % of reported 13F Reported value Filed Source filing
Q3 2026 Added 1,095,740 +15,452 (1.4%) 1.89% $16,238,867 2026-10-09
Q2 2026 Added 1,080,288 +7,052 (0.7%) 0.55% $4,493,998 2026-07-07
Q1 2026 Added 1,073,236 +38,692 (3.7%) 0.53% $3,767,058 2026-04-08
Q4 2025 Added 1,034,544 +519,519 (100.9%) 0.39% $2,824,305 2026-01-14
Q3 2025 New 515,025 +515,025 (0.0%) 0.16% $1,117,604 2025-10-07
Q4 2022 Reduced 0 -63,479 (-100.0%) 0 $0 2023-02-10
Q3 2022 Reduced 63,479 -1,211 (-1.9%) 0.15% $608,000 2022-11-14
Q2 2022 Added 64,690 +21,585 (50.1%) 0.17% $714,000 2022-08-05
Q1 2022 Added 43,105 +3,039 (7.6%) 0.15% $718,000 2022-05-06
Q4 2021 Added 40,066 +14,772 (58.4%) 0.16% $765,000 2022-02-02
Five years are shown. A free account unlocks the complete reported history. Unlock full history

Who else reported the position

368 managers reported IOVANCE BIOTHERAPEUTICS INC for Q3 2026.

Managers reporting IOVANCE BIOTHERAPEUTICS INC in Q3 2026.
Manager Activity Shares Change % of reported 13F Reported value Tenure
BlackRock Inc Added 37,903,960 +946,279 < 0.01% $561,736,688 9 qtrs
MHR FUND MANAGEMENT LLC Unchanged 28,967,103 0 21.06% $429,292,466 16 qtrs
STATE STREET CORPORATION Reduced 21,695,003 -2,783,265 < 0.01% $321,519,944 38 qtrs
VANGUARD CAPITAL MANAGEMENT LLC Added 18,396,706 +192,458 < 0.01% $272,639,183 3 qtrs
TWO SIGMA INVESTMENTS LP Reduced 14,964,996 -4,045,701 0.16% $221,781,241 10 qtrs
VANGUARD PORTFOLIO MANAGEMENT LLC Reduced 12,279,882 -2,109,117 < 0.01% $181,987,851 3 qtrs
GEODE CAPITAL MANAGEMENT LLC Added 10,452,242 +127,416 < 0.01% $154,930,479 38 qtrs
D E Shaw & Co Inc Added 9,163,428 +7,020,294 0.06% $135,802,003 28 qtrs
DIMENSIONAL FUND ADVISORS LP Reduced 6,238,693 -221,756 0.02% $92,443,267 33 qtrs
The Goldman Sachs Group Inc Reduced 4,937,725 -158,609 < 0.01% $73,177,091 38 qtrs
Premium adds each manager's conviction percentile across reporting peers.
Filing details and methodology As reported
Report period
September 30, 2026
Filed
October 09, 2026
Filing type
13F-HR
Position type
COM

Voting authority reported

Sole
1,095,740
Shared
0
None
0

“None” means the manager reported no voting authority for those shares on non-routine matters. It does not disclose why and is not evidence of securities lending.

Form 13-F is a delayed quarter-end snapshot of disclosed long Section 13(f) securities. It can be filed up to 45 days after quarter end, excludes short positions and most non-U.S. securities, and does not reveal intra-quarter trading. For options, reported shares and value describe the underlying-share exposure; strike, expiry, premium, and written positions are not disclosed.